Filtered By:
Drug: Simvastatin

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 124 results found since Jan 2013.

Case presentation: the dancing man from sierra leone
Discussion Making this diagnosis is challenging, as brain imaging often shows non specific changes and blood results are usually normal. CSF may reveal raised proteins and WBCs. A high index of suspicion is required to arrange a brain biopsy as this confirms the diagnosis.
Source: Journal of Neurology, Neurosurgery and Psychiatry - November 14, 2016 Category: Neurosurgery Authors: Al-Rifai, M. S., Salek-Haddadi, A. Tags: Immunology (including allergy), Neuroimaging, Stroke, Radiology, Drugs: musculoskeletal and joint diseases, Vascularitis, Surgical diagnostic tests ABN Annual Meeting, 17-19 May 2016, The Brighton Centre, Brighton Source Type: research

A Case of Transient Global Amnesia: A Review and How It May Shed Further Insight into the Neurobiology of Delusions
Conclusion In closing, our patient’s episode of TGA combined with her emotional and perceptual response lends credence to the proposal of a “fear/paranoia” circuit in the genesis of paranoid delusions—a circuit incorporating amygdala, frontal, and parietal cortices. Here, neutral or irrelevant stimuli, thoughts, and percepts come to engender fear and anxiety, while dysfunction in frontoparietal circuitry engenders inappropriate social predictions and maladaptive inferences about the intentions of others.[54] Hippocampus relays information about contextual information based on past experiences and the current situat...
Source: Innovations in Clinical Neuroscience - April 1, 2016 Category: Neuroscience Authors: ICN Online Editor Tags: Anxiety Disorders Behavioral and Cognitive Neurology Case Report Cognition Current Issue Dementia Medical Issues Neurologic Systems and Symptoms Psychiatry Schizophrenia delusions hippocampus neurobiology Transient global amnesia Source Type: research

Statin use linked to small increase in cataracts risk
Conclusion This research using a large cohort of people from a military healthcare system finds that overall, use of statins for over 90 days was associated with a slight increase in a person’s risk of developing cataracts. Further analyses suggested that the risk was higher among people who did not have any additional diseases. From this the researchers suggest that risk may be higher when statins are given for what is called primary prevention, i.e. given to people with risk factors for cardiovascular disease but who have not yet suffered any cardiovascular disease events such as a heart attack or stroke. The study h...
Source: NHS News Feed - September 20, 2013 Category: Consumer Health News Tags: Medication Older people Heart/lungs Source Type: news

RApid Primary care Initiation of Drug treatment for Transient Ischaemic Attack (RAPID-TIA): study protocol for a pilot randomised controlled trial
DiscussionThis pilot study will be used to estimate key parameters that are needed to design the main study and to estimate the accuracy of primary care diagnosis of TIA. The planned follow-on trial will have important implications for the initial management of people with suspected TIA.Trial registration: ISRCTN62019087
Source: Trials - July 2, 2013 Category: Journals (General) Authors: Duncan EdwardsKate FletcherRachel DellerRichard McManusDaniel LassersonMatthew GilesDon SimsJohn NorrieGraham McGuireSimon CohnFiona WhittleVicky HobbsChristopher WeirJonathan Mant Source Type: research

NICE publishes new draft guidelines on statins use
"Millions more people should be put on cholesterol-lowering statin drugs," BBC News reports. Draft guidance from the National Institute for Health and Care Excellence (NICE) has recommended that the drugs should be given to people with an estimated 1 in 10 or more risk of cardiovascular disease (CVD), which includes conditions such as heart disease and stroke. Statins are medicines that can help lower rates of low-density lipoprotein (LDL) cholesterol (so-called "bad" cholesterol) in the blood. High rates of LDL cholesterol can lead to hardening of the arteries, a risk factor for CVDs. At present,...
Source: NHS News Feed - February 12, 2014 Category: Consumer Health News Tags: Heart/lungs Medication QA articles Source Type: news

'More adults should be taking statins,' says NICE
Conclusion Despite somewhat hysterical media coverage to the contrary ("millions more to be given statins," according to the Daily Express), nobody will be forced to take statins. If your GP does recommend statins, you should ask them to explain the benefits and risks for you personally of starting statin treatment. You may want to find out more about statins before making up your mind – the NHS Choices Health A-Z information on statins is a good place to start. If you do experience troublesome side effects while taking statins, contact your GP or the doctor in charge of your care. It could be the case that a...
Source: NHS News Feed - July 18, 2014 Category: Consumer Health News Tags: Heart/lungs Medication QA articles Source Type: news

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome The IMPROVE-IT Trial
ConclusionsLipid-lowering therapy with ezetimibe plus simvastatin improved clinical outcomes. Reductions in total PEP events, driven by reductions in MI and stroke, more than doubled the number of events prevented compared with examining only the first event. These data support continuation of intensive combination lipid-lowering therapy after an initial CV event. (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial [IMPROVE-IT]; NCT00202878)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - January 25, 2016 Category: Radiology Source Type: research

Statins for acute coronary syndrome.
CONCLUSIONS: Based on moderate quality evidence, due to concerns about risk of bias and imprecision, initiation of statin therapy within 14 days following ACS does not reduce death, myocardial infarction, or stroke up to four months, but reduces the occurrence of unstable angina at four months following ACS. Serious side effects were rare. PMID: 25178118 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - September 1, 2014 Category: Journals (General) Authors: Vale N, Nordmann AJ, Schwartz GG, de Lemos J, Colivicchi F, den Hartog F, Ostadal P, Macin SM, Liem AH, Mills EJ, Bhatnagar N, Bucher HC, Briel M Tags: Cochrane Database Syst Rev Source Type: research

Studies support broader use of cholesterol-lowering statins
The latest guidelines used to determine who should take a cholesterol-lowering statin to prevent heart disease appear to be more accurate and cost-efficient than the previous guidelines. That’s according to two studies led by Harvard researchers, both published in this week’s Journal of the American Medical Association. For many years, the main deciding factor in who needed to take a statin was the level of an individual’s harmful low-density lipoprotein cholesterol (LDL). Updated guidelines published in 2013 by the American College of Cardiology and the American Heart Association moved away from LDL and ...
Source: New Harvard Health Information - July 16, 2015 Category: Consumer Health News Authors: Julie Corliss Tags: Drugs and Supplements cholesterol high cholesterol statins Source Type: news

Effect of Low‐Density Lipoprotein Cholesterol Lowering by Ezetimibe/Simvastatin on Outcome Incidence: Overview, Meta‐Analyses, and Meta‐Regression Analyses of Randomized Trials
ABSTRACT This analysis investigated the extent of different outcome reductions from low‐density lipoprotein cholesterol (LDL‐C) lowering following ezetimibe/simvastatin treatment and the proportionality of outcome to LDL‐C reductions. The authors searched PubMed between 1997 and mid‐June 2015 (any language) and the Cochrane Library to identify all randomized controlled trials comparing ezetimibe/simvastatin with placebo or less intensive LDL‐C lowering. Risk ratios (RR) and 95% confidence intervals (CIs), standardized to 20 mg/dL LDL‐C reduction, were calculated for 5 primary outcomes (fatal and nonfatal) and...
Source: Clinical Cardiology - August 18, 2015 Category: Cardiology Authors: Costas Thomopoulos, George Skalis, Helena Michalopoulou, Costas Tsioufis, Thomas Makris Tags: Review Source Type: research

Lower Transaortic Flow Rate Is Associated With Increased Mortality in Aortic Valve Stenosis
Conclusions In patients with AS without known cardiovascular disease or diabetes, low transaortic FR was independently associated with higher rates of cardiovascular and all-cause mortality. (An Investigational Drug on Clinical Outcomes in Patients With Aortic Stenosis (Narrowing of the Major Blood Vessel of the Heart) (MK-0653A-043 AM4); NCT00092677)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - August 7, 2017 Category: Radiology Authors: Saeed, S., Senior, R., Chahal, N. S., Lonnebakken, M. T., Chambers, J. B., Bahlmann, E., Gerdts, E. Tags: Original Research Source Type: research

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT.
Conclusions -In IMPROVE-IT the benefit of adding ezetimibe to statin was enhanced in patients with DM and in high-risk non-diabetics. Clinical Trial Registration -URL: https://clinicaltrials.gov Unique Identifier: NCT00202878. PMID: 29263150 [PubMed - as supplied by publisher]
Source: Circulation - December 20, 2017 Category: Cardiology Authors: Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park JG, White JA, Bohula E, Braunwald E, IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators Tags: Circulation Source Type: research

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial
Publication date: Available online 2 November 2018Source: The Lancet Diabetes & EndocrinologyAuthor(s): Marc P Bonaca, J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, Eugene BraunwaldSummaryBackgroundPolyvascular disease and type 2 diabetes are each associated with increased cardiovascular risk, but whether these risks are additive is unknown. In this exploratory analysis of a randomised trial, we explored the long-term cardiovascular risk associated with polyvascular disease, type 2 diabetes, and their combination in patients with acute corona...
Source: The Lancet Diabetes and Endocrinology - November 3, 2018 Category: Endocrinology Source Type: research

Mortality and Associated Morbidities Following Traumatic Brain Injury in Older Medicare Statin Users
Conclusion: These findings provide valuable information for clinicians treating older adults with TBI as clinicians can consider, when appropriate, atorvastatin and simvastatin to older adults with TBI in order to decrease mortality and associated morbidities.
Source: The Journal of Head Trauma Rehabilitation - November 1, 2018 Category: Neurology Tags: Focus on Clinical Research and Practice Source Type: research

New Studies Give Mixed Results About Taking Fish Oil and Vitamin D
(CHICAGO) — Taking fish oil or vitamin D? Big studies give long-awaited answers on who does and does not benefit from these popular nutrients. Fish oil taken by healthy people, at a dose found in many supplements, showed no clear ability to lower heart or cancer risks. Same for vitamin D. But higher amounts of a purified, prescription fish oil slashed heart problems and heart-related deaths among people with high triglycerides, a type of fat in the blood, and other risks for heart disease. Doctors cheered the results and said they could suggest a new treatment option for hundreds of thousands of patients like these. ...
Source: TIME: Health - November 10, 2018 Category: Consumer Health News Authors: MARILYNN MARCHIONE / AP Tags: Uncategorized onetime Supplements Source Type: news